Aisling Capital Management LP - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 10, 2026, for the 2025 Q4 period, Aisling Capital Management LP held in its portfolio 13 assets valued at $478,916,332 (i.e. $478.92M).

The most valuable assets in the portfolio included: BridgeBio Pharma Inc. (BBIO) ($389.30M), Syndax Pharmaceuticals, Inc. (SNDX) ($27.67M), and Monte Rosa Therapeutics Inc (GLUE) ($23.09M).

The chart below shows the top 10 valuable assets, and the table below shows the top 13 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Aisling Capital Management LP Portfolio

BridgeBio Pharma Inc. (BBIO)

Syndax Pharmaceuticals, Inc. (SNDX)

Monte Rosa Therapeutics Inc (GLUE)

Bicara Therapeutics Inc. (BCAX)

Compass Pathways Plc (CMPS)

BridgeBio Oncology Therapeutics (BBOT)

CalciMedica, Inc. (CALC)

Scholar Rock Holding Corporation (SRRK)

Biomea Fusion Inc (BMEA)

Urogen Pharma Ltd. (URGN)

Aisling Capital Management LP - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
BridgeBio Pharma Inc. (BBIO)	5089611	389304345	COM
Syndax Pharmaceuticals, Inc. (SNDX)	1316806	27666094	COM
Monte Rosa Therapeutics Inc (GLUE)	1472331	23086150	COM
Bicara Therapeutics Inc. (BCAX)	568919	9574907	COM
Compass Pathways Plc (CMPS)	1198418	8269084	SPONSORED ADS
BridgeBio Oncology Therapeutics (BBOT)	564625	7069105	COM NEW
CalciMedica, Inc. (CALC)	521114	3434141	COM NEW
Scholar Rock Holding Corporation (SRRK)	77031	3393216	COM
Biomea Fusion Inc (BMEA)	2048757	2540459	COM
Urogen Pharma Ltd. (URGN)	108000	2529360	COM
Aclaris Therapeutics Inc (ACRS)	434455	1307710	COM
Marker Therapeutics, Inc. (MRKR)	325370	484801	COM NEW
OnKure Therapeutics, Inc. (OKUR)	88607	256960	COM CL A